Lipocalin 2 expression is associated with aggressive features of endometrial cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Mannelqvist, Monica ^a,b   Stefansson, Ingunn M ^a,b   Wik, Elisabeth ^a,b   Kusonmano, Kanthida ^c   Raeder, Maria B ^a,b   Øyan, Anne M ^a,b   Kalland, Karl Henning ^a,b   Moses, Marsha A ^d,e   Salvesen, Helga B ^a,b   Akslen, Lars A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Uni Research AS   (Norway)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA CATENIN; ESTROGEN RECEPTOR; NERVE CELL ADHESION MOLECULE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; P CADHERIN; PROGESTERONE RECEPTOR; PROTEIN S 100; TRANSCRIPTION FACTOR EZH2; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN B; VASCULOTROPIN C;

ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NORWAY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH; TUMOR RECURRENCE;

ACUTE-PHASE PROTEINS; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIPOCALINS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860532134     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-169     Document Type: Article

References (42)

1. Hraba-Renevey S, Turler H, Kress M, Salomon C, Weil R. SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. Oncogene 1989, 4(5):601-608.
2. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001, 293(5531):829-834. 10.1126/science.1061075, 11486081.
3. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996, 318(Pt 1):1-14. 1217580, 8761444.
4. Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000, 1482(1-2):318-326.
5. Nilsen-Hamilton M, Liu Q, Ryon J, Bendickson L, Lepont P, Chang Q. Tissue involution and the acute phase response. Ann N Y Acad Sci 2003, 995:94-108. 10.1111/j.1749-6632.2003.tb03213.x, 12814942.
6. Miharada K, Hiroyama T, Sudo K, Danjo I, Nagasawa T, Nakamura Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J Cell Physiol 2008, 215(2):526-537. 10.1002/jcp.21334, 18064607.
7. Saiga H, Nishimura J, Kuwata H, Okuyama M, Matsumoto S, Sato S, Matsumoto M, Akira S, Yoshikai Y, Honda K, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol 2008, 181(12):8521-8527.
8. Perry TE, Muehlschlegel JD, Liu KY, Fox AA, Collard CD, Shernan SK, Body SC. Plasma neutrophil gelatinase-associated lipocalin and acute postoperative kidney injury in adult cardiac surgical patients. Anesth Analg 2010, 110(6):1541-1547. 10.1213/ANE.0b013e3181da938e, 2999841, 20435938.
9. Chakraborty S, Kaur S, Muddana V, Sharma N, Wittel UA, Papachristou GI, Whitcomb D, Brand RE, Batra SK. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol 2010, 105(9):2050-2059. 10.1038/ajg.2010.23, 2898914, 20179686.
10. D'Anna R, Baviera G, Giordano D, Todarello G, Russo S, Recupero S, Bolignano D, Corrado F. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2010, 89(2):275-278. 10.3109/00016340903443676, 19961280.
11. Marti J, Fuster J, Hotter G, Sola AM, Deulofeu R, Modolo MM, Loera MA, Ferrer J, Fondevila C, Garcia-Valdecasas JC. Serum neutrophil gelatinase-associated lipocalin in patients with colorectal liver metastases: preliminary results of an exploratory prospective study. Int J Biol Markers 2010, 25(1):21-26.
12. Yang HN, Boo CS, Kim MG, Jo SK, Cho WY, Kim HK. Urine neutrophil gelatinase-associated lipocalin: an independent predictor of adverse outcomes in acute kidney injury. Am J Nephrol 2010, 31(6):501-509. 10.1159/000309841, 20453495.
13. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009, 106(10):3913-3918. 10.1073/pnas.0810617106, 2656179, 19237579.
14. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008, 98(9):1540-1547. 10.1038/sj.bjc.6604329, 2391106, 18392050.
15. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009, 89(5):531-548. 10.1038/labinvest.2009.17, 19308044.
16. Cho H, Kim JH. Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 2009, 57(5):513-521. 10.1369/jhc.2009.953257, 2675069, 19188485.
17. Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011, 71(15):5090-5100. 10.1158/0008-5472.CAN-11-0568, 3148311, 21653680.
18. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, Quinn MA, Rice GE. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 2007, 120(11):2426-2434. 10.1002/ijc.22352, 17294443.
19. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty A, Bresalier RS, et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 2008, 68(15):6100-6108. 10.1158/0008-5472.CAN-08-0540, 2714276, 18676832.
20. Venkatesha S, Hanai J, Seth P, Karumanchi SA, Sukhatme VP. Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res 2006, 4(11):821-829. 10.1158/1541-7786.MCR-06-0110, 17114340.
21. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11(15):5390-5395. 10.1158/1078-0432.CCR-04-2391, 16061852.
22. Miyamoto T, Kashima H, Suzuki A, Kikuchi N, Konishi I, Seki N, Shiozawa T. Laser-captured microdissection-microarray analysis of the genes involved in endometrial carcinogenesis: stepwise up-regulation of lipocalin2 expression in normal and neoplastic endometria and its functional relevance. Hum Pathol 2011, 42(9):1265-1274. 10.1016/j.humpath.2010.07.027, 21334721.
23. Miyamoto T, Asaka R, Suzuki A, Takatsu A, Kashima H, Shiozawa T. Immunohistochemical detection of a specific receptor for lipocalin2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma. Exp Mol Pathol 2011, 91(2):563-568. 10.1016/j.yexmp.2011.06.002, 21763306.
24. Liao CJ, Huang YH, Au HK, Wang LM, Chu ST. The cancer marker neutrophil gelatinase-associated lipocalin is highly expressed in human endometrial hyperplasia. Mol Biol Rep 2011, 39(2):1029-1036.
25. Lin HH, Liao CJ, Lee YC, Hu KH, Meng HW, Chu ST. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci 2011, 7(1):74-86. 3030144, 21278918.
26. Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008, 32(2):307-316.
27. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004, 22(7):1242-1252. 10.1200/JCO.2004.09.034, 15051772.
28. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004, 44(5):472-479. 10.1111/j.1365-2559.2004.01882.x, 15139995.
29. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008, 199(5):e541-e547. 543..
30. Mannelqvist M, Stefansson I, Salvesen HB, Akslen LA. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology 2009, 54(2):174-183. 10.1111/j.1365-2559.2008.03201.x, 19207942.
31. Mannelqvist M, Stefansson IM, Bredholt G, Bø TH, Øyan AM, Jonassen I, Kalland K-H, Salvesen HB, Akslen LA. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 2010, 178(2):861-871.
32. Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 2006, 66(6):3303-3309. 10.1158/0008-5472.CAN-05-1163, 16540684.
33. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2(7):811-814. 10.1038/nm0796-811, 8673929.
34. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009, 106(12):4834-4839. 10.1073/pnas.0806514106, 2660768, 19261849.
35. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008, 108(3):389-397. 10.1007/s10549-007-9619-3, 17554627.
36. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61(16):5979-5984.
37. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 1998, 79(6):565-572. 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.0.CO;2-F, 9842963.
38. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011, 9(2):133-148. 10.1158/1541-7786.MCR-10-0394, 3078037, 21228116.
39. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol 2011, 32(3):441-450. 10.1007/s13277-010-0137-2, 21153724.
40. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006, 24(2):268-273.
41. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100(20):11606-11611. 10.1073/pnas.1933744100, 208805, 14500907.
42. Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun 2012, 4(1):31-40. 10.1159/000330095, 21912088.